RNS Number : 3470H
MyCelx Technologies Corporation
06 May 2025
 

 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

6 May 2025

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

PFAS Contract Award

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to announce the award of a short-term rental contract for a mobile PFAS treatment system to treat groundwater contamination at a site in North Dakota for the U.S. Department of Defense (DoD).

 

The original contract for PFAS treatment is for three months, but we believe volumes will increase so we are anticipating the rental potentially extending beyond the original term. As part of the project, MYCELX is conducting in-house treatability analysis to assess groundwater characteristics and predict system performance, enabling the Company to optimize PFAS removal efficiency on site. The ability to perform in-house treatability analyses accelerates sales timelines by giving MYCELX control over the testing process ultimately decreasing the amount of time to determine system design.

 

The contract is included in the Company's revenue forecasts for the 2025 financial year. It reflects the continued validation of MYCELX's innovative solutions by major clients with numerous sites, such as the DoD, who has assessed 718 sites to date and moved more than 50% to the next investigative phase which will require effective solutions such as MYCELX for long-term cleanups. According to the U.S. Government Accountability Office, remediation costs will continue to increase as the DoD learns more about the extent of PFAS releases. This is a decades long cleanup and working with the DoD now gives the Company more reference projects that can be promoted within the DoD as well as with other similar application projects.  

 

Connie Mixon, CEO, commented:

 

"Working with the Department of Defense on this PFAS remediation project as a very positive step forward for MYCELX. We have focused significant time and resources on developing our offering in the PFAS remediation market and being selected for contracts with the DoD demonstrates that our systems are cost effective, high performing, and reliable. We will shortly be involved in two highly anticipated PFAS trials, which, if successful, have the potential to convert into further commercial sales contracts in due course. As a team, we are very excited about the U.S.EPA's recent notification of plans to support PFAS remediation in the U.S., which we believe will create urgency and confidence for decision makers to move on clean up timelines. We look forward to keeping all of our stakeholders updated on our progress over the remainder of 2025."

 

 For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Dan Hodkinson (Corporate Finance)

Ondraya Swanson (Corporate Broking)

Jasper Berry / Michael Johnson (Sales)

 

 

 

Tel: +44 20 7220 0500

 

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRGZGGKKKFGKZM